Synthesis and antiviral evaluation of some β-L-2',3'-dideoxy-5-chloropyrimidine nucleosides and pronucleotides

Antiviral Research

Volumn 45, Issue 3, 2000, Pages 169-183

  Pierra, Claire ^a   Imbach, Jean Louis ^a   De Clercq, Erik ^b   Balzarini, Jan ^b   Van Aerschot, Arthur ^b   Herdewijn, Piet ^b   Faraj, Abdesslem ^c   Loi, Anna G ^c   Sommadossi, Jean Pierre ^c   Gosselin, Gilles ^a  

^a CNRS   (France)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

L Dideoxynucleoside enantiomers; Hepatitis B virus; Human immunodeficiency virus; Pronucleotides

Indexed keywords

LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; ENANTIOMER; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LIVER CELL; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CELL LINE; DIDEOXYNUCLEOSIDES; HEPATITIS B VIRUS; HIV; HIV-1; HIV-2; HUMANS; MOLECULAR STRUCTURE; STEREOISOMERISM;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034162945     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00069-3     Document Type: Article

References (45)

1. Alexander P., Holy A. Prodrugs of analogs of nucleic acid components. Collec. Czech. Chem. Commun. 59:1994;2127-2165.
2. Andrei G., De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 14:1990;287-300.
3. Arzumanov A.A., Dyatkina N.B. Modified nucleoside phosphates as precursors of antiviral and antitumor compounds in cells (Review). Russ. J. Bioorg. Chem. 22:1996;709-725.
4. Balzarini J., De Clercq E., Mertes M.P., Shugar D., Torrence P.F. 5-Substituted 2′-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochem. Pharmacol. 31:1982;3673-3682.
5. Balzarini J., Masanori B., Pauwels R., Herdewijn P., De Clercq E. Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 37:1988;2847-2856.
6. Balzarini J., Van Aerschot A., Herdewijn P., De Clercq E. 5-Chloro-substituted derivatives of 2′,3′-didehydro-2′,3′-dideoxyuridine, 3′-fluoro-2′,3′-dideoxyuridine and 3′-azido-2′,3′-dideoxyuridine as anti-HIV agents. Biochem. Pharmacol. 38:1989;869-874.
7. Balzarini J., Van Aerschot A., Pauwels R., Baba M., Schols D., Herdewijn P., De Clercq E. 5-Halogeno-3′-fluoro-2′,3′-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3′-fluoro-2′,3′-dideoxy-5-chlorouridine. Mol. Pharmacol. 35:1989;571-577.
8. Balzarini J., Holy A., Jindrich J., Naesens L., Snoeck R., Schols D., De Clercq E. Differential antiherpesvirus and antiretrovirous effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37:1993;332-338.
9. Barton D.H.R., McCombie S.W. A new method for the deoxygenation of the secondary alcohols. J. Chem. Soc. Perkin Trans. 1:1975;1574-1585.
10. Cava M.P., Levinson M.I. Thionation reactions of Lawesson's reagents. Tetrahedron. 41:1985;5061-5087.
11. Daluge S.M., Purifoy D.J.M., Savina P.M., St Clair M.H., Parry N.R., Dev I.K., Novak P., Ayers K.M., Reardon J.E., Roberts G.B., Fyfe J.A., Blum M.R., Averett D.R., Dornsife R.E., Domin B.A., Ferone R., Lewis D.A., Krenitsky T.A. 5-Chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1994;1590-1603.
12. De Clercq E., Merigan T.C. Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (poly rI).(poly rC). Proc. Soc. Exp. Biol. Med. 137:1971;590-593.
13. De Clercq, E., Luczak, M., Reepmeyer, J.C., Kirk, K.L., Cohen, L.A., 1975. Fluoroimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sci. 17, 187-194.
14. De Clercq E., Descamps J., Verhelst G., Walker R.T., Jones A.S., Torrence P.F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 141:1980;563-574.
15. El Alaoui M.A., Faraj A., Pierra C., Boudou V., Johnson R., Mathé C., Gosselin G., Korba B.E., Imbach J.-L., Schinazi R.F., Sommadossi J.-P. Inhibition of hepatitis B virus replication by nucleoside enantiomers of β-2′,3′-dideoxypurine analogues. Antiviral Chem. Chemother. 7:1996;276-280.
16. Gao W.-Y., Agbaria R., Driscoll J.S., Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:1994;12633-12638.
17. Gosselin G., Bergogne M.-C., Imbach J.-L. Synthesis and antiviral evaluation of β-L-xylofuranosyl nucleosides of the five naturally occuring nucleic acid bases. J. Heterocycl. Chem. 30:1993;1229-1233.
18. Gosselin G., Mathé C., Bergogne M.-C., Aubertin A.-M., Kirn A., Schinazi R.F., Sommadossi J.-P., Imbach J.-L. Enantiomeric 2′,3′-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. C. R. Acad. Sci. Ser. III. 317:1994;85-89.
19. Gosselin G., Schinazi R.F., Sommadossi J.-P., Mathé C., Bergogne M.-C., Aubertin A.-M., Kirn A., Imbach J.-L. Anti-human immunodeficiency virus activities of the β-L-enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1994;1292-1297.
20. Hantz O., Périgaud C., Borel C., Jamard C., Zoulim F., Trépo C., Imbach J.-L., Gosselin G. The SATE pronucleotide approach applied to acyclovir. Part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. Antiviral Res. 40:1999;179-197.
21. Herdewijn P. Structural requirements for antiviral activity in nucleosides. Drug Discovery Today. 2:1997;235-242.
22. Herdewijn P., Van Aerschot A., Kerremans L. Synthesis of nucleosides fluorinated in the sugar moiety. The application of diethylaminosulfur trifluoride to the synthesis of fluorinated nucleosides. Nucleosides Nucleotides. 8:1989;65-96.
23. Herdewijn P., Van Aerschot A., Balzarini J., De Clercq E. 3′-Fluoro- and 3′-azido-substituted 2′,3′-dideoxynucleosides: structure-activity relationship. Med. Chem. Res. 1:1991;9-19.
24. Ishido Y., Nakazaki N., Sakairi N. Partial deprotection of carbohydrate derivatives. Part 3. Regioselective 2′-O-deacylation of fully acylated purine and pyrimidine ribonucleosides with hydrazine hydrate. J. Chem. Soc. Perkin Trans. 1:1979;2088-2098.
25. Jeong, L.S., Schinazi, R.F., Beach, J.W., Kim, H.O., Nampalli, S., Shanmuganathan, K., Alves, A.J., McMillan, A., Chu, C.K., Mathis, R., 1993. Asymmetric synthesis and biological evaluation of β-L-(2R,5S)- and α-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleoside as potential anti-HIV agents. J. Med. Chem. 36, 181-195.
26. Jones R.J., Bischofberger N. Mini review: nucleotide prodrugs. Antiviral Res. 27:1995;1-17.
27. Kinchington D., Gee S., Balzarini J., Gait M., De Clercq E., Field H.J. Current antiviral agents factfile. 4th Edition: Part IIhuman immunodeficiency viruses. Int. Antiviral News. 6:1998;188-204.
28. Korba B.E., Guerin J.-L.G. Use of standarized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19:1992;55-70.
29. Krise J.P., Stella V.J. Review: prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Deliv. Rev. 19:1996;287-310.
30. Lefebvre I., Perigaud C., Pompon A., Aubertin A.-M., Girardet J.-L., Kirn A., Gosselin G., Imbach J.-L. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38:1995;3941-3950.
31. Lin T.-S., Luo M.-Z., Liu M.-C., Pai S.B., Dutschman G.E., Cheng Y.-C. Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:1994;171-174.
32. Lin T.-S., Luo M.-Z., Liu M.-C., Pai S.B., Dutschman G.E., Cheng Y.-C. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. Med. Chem. 37:1994;798-802.
33. Matthes E., Lehmann C., Von Janta-Lipinski M., Scholz D. Inhibition of HIV-replication by 3′-fluoro-modified nucleosides with low cytotoxicity. Biochem. Biophys. Res. Commun. 165:1989;488-495.
34. Meier, C., 1998. Pro-Nucleotides-Recent Advances in the Design of Efficient Tools for the Delivery of Biologically Active Nucleoside Monophosphates. Synlett, pp. 233-242.
35. Pankiewicz K.W., Krzeminski J., Ciszewski L.A., Ren W.-Y., Watanabe K.A. A synthesis of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine and hypoxantine. An effect of C3′-endo to C2′-endo conformational shift on the reaction course of 2′-hydroxyl group with DAST. J. Org. Chem. 57:1992;553-559.
36. Périgaud C., Gosselin G., Imbach J.-L. Mini review: from the pronucleotide concept to the SATE phosphate protecting groups. Alexander J.C. Current Topics in Medicinal Chemistry. 2:1997;15-29 Blackwell Science, Oxford.
37. Périgaud C., Gosselin G., Girardet J.-L., Korba B.E., Imbach J.-L. The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir. Antiviral Res. 40:1999;167-178.
38. Perry C.M., Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 53:1997;657-680.
39. Riddler S.A., Wang L.H., Bartlett J.A., Savina P.M., Packard M.V., McMahon D.K., Blum M.R., Dunn J.A., Elkins M.M., Mellors J.W. Safety and pharmacokinetics of 5-chloro-2′,3′-dideoxy-3′-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 40:1996;2842-2847.
40. Schinazi R.F., Gosselin G., Faraj A., Korba B.E., Liotta D.C., Chu C.K., Mathé C., Imbach J.-L., Sommadossi J.-P. Pure nucleoside enantiomers of (-2′,3′-dideoxycytidine analogues are selective inhibitors of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 38(9):1994;2172-2174.
41. Sommadossi J.-P. Nucleoside analogs: similarities and differences. Clin. Infect. Dis. 16:1993;S7-S15.
42. Van Aerschot A., Herdewijn P., Balzarini J., Pauwels R., De Clercq E. 3′-Fluoro-2′,3′-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2′- and 3′-fluorinated 2′,3′-dideoxynucleoside analogues. J. Med. Chem. 32:1989;1743-1749.
43. Van Aerschot A., Everaert D., Balzarini J., Augustyns K., Jie L., Janssen G., Peeters O., Blaton N., De Ranter C., De Clercq E., Herdewijn P. Synthesis and anti-HIV evaluation of 2′,3′-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2′,3′-dideoxynucleosides. J. Med. Chem. 33:1990;1833-1839.
44. Wang P., Hong J.H., Cooperwood J.S., Chu C.K. Mini review: recent advances in l-nucleosides: chemistry and biology. Antiviral Res. 40:1998;19-44.
45. Witvrouw M., Daelemans D., Pannecouque C., Neyts J., Andrei G., Snoeck R., Vandamme A.-M., Balzarini J., Desmyter J., Baba M., De Clercq E. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antiviral Chem. Chemother. 9:1998;403-411.